Menu
Back to Journals » Drug Design, Development and Therapy » Volume 12
RETRACTED ARTICLE: A novel ocular delivery of brinzolamide based on gellan gum: in vitro and in vivo evaluation
Received 6 October 2017
Accepted for publication 30 November 2017
Published 23 February 2018 Volume 2018:12 Pages 383—389
DOI https://doi.org/10.2147/DDDT.S153405
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Qiongyu Guo
This paper has been retracted.
Sun J, Zhou Z. Drug Des Devel Ther. 2018;12:383–389.
The Editor and Publisher of the Drug Design, Development and Therapy wish to retract the published article. Concerns were raised regarding the alleged duplication of images in Figure 2 with the same images from Figure 1 in Zhu et al, 2015 ‘A novel in situ gel base of deacetylase gellan gum for sustained ophthalmic drug delivery of ketotifen: in vitro and in vivo evaluation’ (https://doi.org/10.2147/DDDT.S87368).
The authors did not respond to our queries and no explanation for the alleged image duplication was provided. The Editor determined that the reported findings were unreliable and requested to retract the article. The authors were notified of this.
We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
© 2018 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.